Hikma Pharmaceuticals (HIK) Earns Hold Rating from Numis Securities
Several other research firms also recently weighed in on HIK. Barclays reiterated an equal weight rating on shares of Hikma Pharmaceuticals in a report on Wednesday, December 19th. Jefferies Financial Group upgraded shares of Hikma Pharmaceuticals to a buy rating and lifted their target price for the company from GBX 1,643 ($21.47) to GBX 2,000 ($26.13) in a report on Tuesday, November 27th. Peel Hunt reiterated a hold rating on shares of Hikma Pharmaceuticals in a report on Thursday, December 6th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Hikma Pharmaceuticals from GBX 1,050 ($13.72) to GBX 1,900 ($24.83) and gave the company a neutral rating in a report on Tuesday, November 20th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average target price of GBX 1,835.71 ($23.99).
HIK stock opened at GBX 1,598.50 ($20.89) on Wednesday. Hikma Pharmaceuticals has a one year low of GBX 844.40 ($11.03) and a one year high of GBX 2,089 ($27.30). The company has a debt-to-equity ratio of 46.76, a quick ratio of 1.11 and a current ratio of 1.90. The company has a market cap of $3.86 billion and a PE ratio of -4.77.
In other Hikma Pharmaceuticals news, insider Mazen Darwazah purchased 20,000 shares of the company’s stock in a transaction on Wednesday, March 13th. The stock was acquired at an average price of GBX 1,582 ($20.67) per share, for a total transaction of £316,400 ($413,432.64). Also, insider Mary (Nina) Henderson purchased 2,000 shares of the company’s stock in a transaction on Friday, March 15th. The stock was acquired at an average price of GBX 1,563 ($20.42) per share, with a total value of £31,260 ($40,846.73).
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.
Featured Article: What is a Futures Contract?
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.